GTx
GTx was a Memphis biotech that developed selective androgen receptor modulators, including enobosarm for cancer-related muscle wasting and breast cancer, before merging with Oncternal Therapeutics in 2019.
Overview
GTx Incorporated, founded in 1997 in Memphis, Tennessee, worked on selective androgen receptor modulators and toremifene. Its phase 3 POWER trials tested enobosarm against muscle wasting in non-small cell lung cancer, and later studies explored it in androgen receptor-positive breast cancer; a toremifene programme for prostate cancer patients on androgen deprivation was also taken to phase 3. GTx merged with Oncternal Therapeutics in 2019. Its trials remain on ClinicalTrials.gov under GTx as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyAchieve Life Sciences (formerly OncoGenex)
Shares Prostate cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Prostate cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyVeru
Shares Prostate cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Prostate cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Prostate cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySOTIO Biotech
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.